Understanding how chemotherapy affects heart health
Unraveling the role of endothelium in chemotherapy-induced cardiotoxicity
This study is looking at how the chemotherapy drug doxorubicin can harm the heart, especially the cells that line the blood vessels, to help find better ways to protect your heart during cancer treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11004007 on NIH RePORTER |
What this research studies
This research investigates the harmful effects of the chemotherapy drug doxorubicin on heart function, specifically focusing on how it causes damage to the heart's endothelial cells. By exploring the underlying mechanisms of chemotherapy-induced cardiotoxicity, the study aims to identify the ways in which doxorubicin disrupts normal heart physiology. The research will involve examining different cardiac cell types and their interactions over time to better understand the long-term impacts of treatment. Patients may benefit from insights that could lead to improved therapies and protective strategies against heart damage caused by chemotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are being treated with doxorubicin and are at risk of developing heart-related side effects.
Not a fit: Patients who are not receiving doxorubicin or those with pre-existing severe heart conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better treatment protocols that minimize heart damage in cancer patients receiving chemotherapy.
How similar studies have performed: Previous research has shown promising results in understanding chemotherapy-induced cardiotoxicity, but this specific focus on endothelial mechanisms is relatively novel.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Sayed, Nazish — Stanford University
- Study coordinator: Sayed, Nazish
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.